Republic Services Inc. Common Stock vs BIO-TECHNE Corp — how do they compare? Republic Services Inc. Common Stock trades at $229.12 (market cap $68.73B), while BIO-TECHNE Corp trades at $72.55 (market cap $11.37B). The key difference: Republic Services Inc. Common Stock is far larger — about 6× BIO-TECHNE Corp's market cap, and Republic Services Inc. Common Stock pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| RSG | TECH | |
|---|---|---|
Market Cap | $68.73B | $11.37B |
Volume | 1,226,777 | 1,544,768 |
Sector | Industrials | Health |
52-Week High | $232.27 | $72.61 |
52-Week Low | $197.73 | $43.31 |
Enterprise Value | $82.91B | $11.40B |
Dividend Yield | 1.19% | 0.44% |
Typical Hold Time | — | 64 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Bio-Techne (TECH) trades at $72.52, near its 52-week high of $72.70, with a slight 0.06% daily gain. Technical indicators show a bullish trend, while valuation ratios like a P/E of 62.52 suggest premium pricing. Recent shareholder approval of its acquisition by Merck KGaA at $73.00 per share is a key catalyst, alongside consistent earnings beats in two of the last three quarters. Cash flow trends improved in 2026, with net cash flow reaching $103 million, indicating stronger financial health.
The stock's upside is capped by the acquisition offer, but fundamentals like a 65.77% gross margin and positive analyst sentiment (46% buy ratings) support stability. Risks include integration challenges post-acquisition and elevated valuation metrics. Near-term performance hinges on Q3 2026 earnings against a $0.4433 EPS expectation, with the $73.00 buyout price acting as a resistance level.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Republic Services Inc. is a waste management company that provides non-hazardous solid waste collection, transfer, disposal, and recycling services across North America.
Read more on RSG →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →